Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott C Morgan

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Cancer|October 13, 2024
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelinesAhmad Mousa, David-Dan Nguyen, Aly-Khan Lalani, et al.
European Urology|August 17, 2021
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Samir Patel, Scott A North, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2022
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in CanadaBobby Shayegan, Christopher J D Wallis, Robert J Hamilton, et al.
Urologic Oncology|February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in CanadaBobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Cancer|October 13, 2024
Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelinesAhmad Mousa, David-Dan Nguyen, Aly-Khan Lalani, et al.
European Urology|August 17, 2021
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Samir Patel, Scott A North, et al.
Prostate Cancer and Prostatic Diseases|February 24, 2022
Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in CanadaBobby Shayegan, Christopher J D Wallis, Robert J Hamilton, et al.
Urologic Oncology|February 26, 2022
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in CanadaBobby Shayegan, Christopher J D Wallis, Shawn Malone, et al.
BJUI Compass|August 11, 2022
Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based studyShawn Malone, Christopher J D Wallis, Richard Lee-Ying, et al.
The Lancet. Oncology|November 18, 2022
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)Shankar Siva, Muhammad Ali, Rohann J M Correa, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Forecasting Trends in Androgen Deprivation Therapy Intensification for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Population-Based Cohort and Time-Series AnalysisEalia Khosh Kish, Erind Dvorani, Refik Saskin, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline UpdateKatherine S Virgo, R Bryan Rumble, Ronald de Wit, et al.
European Urology Oncology|July 10, 2024
Long-term Renal Function Outcomes After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma Including Patients with a Solitary Kidney: A Report from the International Radiosurgery Oncology Consortium of the KidneyVivian S Tan, Rohann J M Correa, Andrew Warner, et al.
Pageof 8